Introduction
In the central nervous system (CNS) under normal conditions, NO appears to have a number of key functions [l]. It is synthesized by various isoforms of NO synthase (NOS), which catalyse the conversion of arginine into citrulline resulting in the liberation of NO [2] . In general, neurons produce NO by a Ca2+-dependent activation of neuronal NOS (nNOS) which is constitutively expressed [2] . However, in glial cells such as astrocytes, NO synthesis is largely Ca2+-independent and requires induction of NOS (iNOS), i.e. de n o w enzyme synthesis [3] .
A third isoform of NOS (eNOS) has also been reported in the CNS and is associated with the brain vasculature [l]. All isoforms have a number of cofactor requirements, e.g. NADPH, FMN and tetrahydrobiopterin (BH,) [2] .
Activation of nNOS forms part of the pathway triggered by glutamate receptor activation, which leads ultimately to intracellular cGMP elevation, whereas induction of iNOS is associated with pathological conditions such as infection [ 
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Abbreviations used: BH4, tetrahydrobiopterin; CNS, central nervous system; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; MS, multiple sclerosis; N U , N-acetylaspartate; NOS, nitric oxide synthase. $To whom correspondence should be addressed. Despite important physiological roles for NO, excessive or inadequate formation of this compound has been suggested to be an important factor in the aetiology of neurological disorders [6-81. In addition, there is an increasing body of evidence to support the concept that disruption of brain energy metabolism may underlie the neurodegenerative process [9] . Thus it is the aim of this paper to explore the potential links between these observations; namely is there a role for NO-mediated perturbations of brain energy metabolism in the development of neurological disorders?
Cellular targets of N O
Within the cell, the mitochondrial respiratory chain appears to be an important target for NO. [12, 13] . This enzyme has been demonstrated to be modified by exposure to NO in a number of diverse biological preparations [ 13,141. In the presence of NO and/or ONOO-, a cysteine residue in the active site of the enzyme is believed to be nitrosylated resulting in covalent linkage of NAD' to the enzyme and loss of activity [12, 15] . The observation that covalent modification of G3PDH is apparent in normal rat brain has led to the suggestion that NO-mediated regulation of G3PDH activity occurs under normal physiological conditions and hence may be a mechanism for regulating cellular energy metabolism [121*
Cellular toxicity and differential susceptibility to NO
The different mechanisms for enhancing NO synthesis in neurons and glial cells have prompted suggestions that excessive generation by either nNOS or iNOS may be important in pathophysiological processes in the CNS. Thus, with regard to excitotoxicity, i.e. neurotoxicity arising from exposure of neurons to glutamate, elevation of the intracellular Ca2+ concentration may increase nNOS activity [16] . However, this suggestion is controversial, with some laboratories being unable to demonstrate any involvement of NO in glutamate-mediated toxicity [ 17,181. Despite such discrepancies, prolonged exposure of various cell types to NO appears to be toxic. T h e detailed mechanisms by which NO exerts its deleterious effects are not known, but are likely to be mediated by ONOO-, since NO toxicity appears to be considerably enhanced in the presence of 0;' [3, 19] .
In view of the observations that the mitochondrial respiratory chain is particularly susceptible to damage by ONOO- [6, 20] , it is tempting to speculate that an ensuing cellular energy deficiency state is the likely mechanism for NOmediated toxicity. However, despite marked loss in the activities of complexes II/III and IV in astrocytes after induction of iNOS, cell death was not apparent 131. T h e apparent resistance of these cells appears to be mediated by a compensatory increase in glycolysis, i.e. there was a marked increase in glucose consumption coupled with lactate formation [3] . This switch to anaerobic respiration would appear to be at odds with the suggestion that inhibition of G3PDH activity occurs in the presence of increased NO/ONOOavailability [12, 13] . In order to address this further, we have measured G3PDH activity in cytosolic fractions prepared from astrocytes treated, as before [3] , to induce iNOS. Under such conditions G3PDH activity was decreased by 33% (133.2f 17.8 nmol/min per mg of protein in controls compared with 89.7f8.8 nmol/min per mg in the presence of lipopolysaccharide + interferon y; data expressed as the meanfS.E.M. for five independent cell culture preparations; P < 0.05).
Furthermore this decrease in enzyme activity was prevented by treatment of the astrocytes with the NOS inhibitor, @-monomethylarginine.
T h e logical conclusion from this observation is that, as a result of ONOO--mediated mitochondria1 damage, glycolytic flux is enhanced despite loss of G3PDH activity, i.e. G3PDH activity is not a rate-limiting step for glycolysis under the conditions employed.
In contrast with astrocytes, neurons appear to be particularly vulnerable to the actions of ONOO-, i.e. brief ( < 5 min) exposure of neurons to ONOO-results in irreversible mitochondrial damage and cell death within 24 h [6] . This vulnerability may arise from an inability to sustain cellular energy demands by glycolysis and an inferior capacity to handle oxidizing species such as ONOO- [6] . With regard to the latter suggestion, the intracellular GSH concentration may be particularly important, since O N 0 0 -reacts with thiol-containing compounds such as GSH [6] . Various lines of evidence now appear to confirm the suggestion that the intracellular GSH status is important in dictating susceptibility to ONOO-: (1) astrocyte GSH concentration appears to be approximately double that of neurons cultured under comparable conditions, possibly as a result of a superior GSH-biosynthetic capacity [6, 21] ; (2) astrocytes only appear vulnerable to acute ONOO-exposure when the GSH concentration is decreased as result of pretreatment with 1,-buthionine sulphoximine, a specific inhibitor of GSH biosynthesis [22] .
Astrocyte-derived NO and neuronal damage
In view of the diffusible nature of NO and ONOO-, the inherent resistance of astrocytes to these molecules and the ability of these cells to generate NO and ONOO-for sustained periods, Volume 25 it has been proposed that, in certain pathological conditions, astrocytic-derived NO and ONOOmay cause mitochondrial damage in susceptible target cells such as neurons [6, 22] .
Multiple sclerosis (MS)
MS is a demyelinating disorder of the CNS which is of unknown aetiology. However, analysis of cerebrospinal fluid from patients in the active phase of MS revealed an approx. 70% increase in the NO/ONOO--degradation products, NO; plus NO; [23] . Further evidence for an involvement of NO in MS has come from post-mortem studies, which have detected in the MS brain elevated levels of mRNA coding for iNOS and nitrotyrosine residues, indicating ONOO-formation [24, 25] . In addition, NADPH diaphorase activity, which forms the basis of an histochemical stain possibly relating to NOS catalytic activity, has been detected in astrocytes associated with actively demyelinating lesions [24] .
Whether NO or ONOO-generated by astrocytes causes neuronal mitochondrial damage in MS remains to be demonstrated. However, evidence for neuronal mitochondrial damage in MS comes from observations relating to brain N-acetylaspartate (NAA) concentration. NAA is synthesized exclusively in the mitochondrial matrix of neurons and its concentration appears to depend on mitochondrial integrity [26, 27] . Using NMR spectroscopy, a reduction in the NAA signal has been described in MS plaques [28] . Furthermore this decrease in NAA concentration appears in some cases to be reversible and hence may reflect events preceding neuronal loss [28] .
The mitochondria of oligodendrocytes also appear to be sensitive to NO [7] . Consequently, in MS, it is feasible that astrocyte-derived NO and ONOO-impairs the ability of oligodendrocytes to synthesize myelin by causing a cellular energy deficiency state in these cells.
Parkinson's and Alzheimer's disease
The potential involvement of NO and ONOOhas been considered in Parkinson's and Alzheimer's disease. One study has identified NADPH diaphorase-positive glial cells in the substantia nigra of post-mortem brains obtained from patients with Parkinson's disease [29] . Since loss of nigral GSH is also considered to be a key event in the pathogenesis of Parkinson's disease [30] , decreased scavenging of ONOOmay occur leading to the increased possibility of mitochondrial damage. In view of the apparent specific loss of complex-I activity in Parkinson's disease [31] , it is of note that this component of the respiratory chain is particularly susceptible to the actions of ONOO-when cellular GSH levels are compromised [22, 32] .
The glial-derived factor Sloop, which is overexpressed in Alzheimer's disease, has been shown to induce iNOS in cultured rat astrocytes, suggesting a possible role for overproduction of NO and hence ONOO-in the pathology of this disorder [33] . Evidence for mitochondrial damage, particularly at the level of complex IV, has also been reported in the cerebral cortex of individuals who died with Alzheimer's disease [34] . Whether this loss of mitochondrial function is due to increased ONOO-generation is not known.
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Possible beneficial effects of enhanced NO formation
Considerable attention has been paid to the possible deleterious effects of NO and ONOO-in the pathogenesis of neurodegenerative disorders. It is, however, possible that, at certain stages of a disease process, formation of these molecules may actually be beneficial. In this light it has been proposed that NO might inhibit T-cell activation and cell trafficking across the blood-brain barrier, thus minimizing the autoimmune cascade associated with MS [35] .
Impaired NO synthesis
In view of the important physiological roles assigned to NO, it is possible that a diminished NO-biosynthetic capacity may also have pathological consequences.
BH, deficiency
BH4 is an obligatory cofactor for all isoforms of NOS and the aromatic amino acid mono-oxygenases [2, 36] . Consequently, in the inborn errors of BH4 metabolism, which now include some forms of dopa-responsive dystonia, there is an impaired ability to synthesize dopamine and 5-hydroxytryptamine [36, 37] . In contrast, the effect of BH4 deficiency on brain NO metabolism is at present poorly understood.
Using the hph-1 mouse, which displays BH4 deficiency [8] , we have investigated the effects of limited BH4 availability on brain NO metabolism. Our observations to date suggest that, as a consequence of this cofactor deficiency, there is a marked impairment in the ability to synthesize NO and thus cGMP [38] . In view of this finding and the apparent sensitivity of G3PDH to NO, we have measured G3PDH activity in cytosolic fractions prepared from control and hph-1 mouse brains.
When compared with the control preparations, the specific activity of G3PDH activity was found to be fourfold greater in the hph-1 mice (Figure 1 ). T h e biochemical consequences of this finding for brain energy metabolism are not clear since this enzyme would not appear to be a rate-limiting factor for glycolysis, as discussed above. However, this observation may lend further support to the concept that the activity of this enzyme is normally regulated by NO. If this is the case, then it is possible that the need for tight control arises as a result of functions of this enzyme unrelated to glycolysis.
Recently, G3PDH has been shown to interact with P-amyloid precursor protein [39] and the polyglutamine tracts that are expressed in neurodegenerative disorders such as spinocerebellar ataxia and Huntingdon's disease [40] . Whether such interactions increase or decrease the susceptibility of neurons to insults that initiate the neurodegenerative process are as yet not known.
Treatment of the CNS symptoms in children with disorders of BH4 metabolism is focused on the correction of monoamine metabo-G3PDH activity in the cytosolic fraction of brains prepared from 30-day-old control and hph-I mice Data are expressed as meansfS.E.M., n = 8 for control and 6 for hph-I preparations. Statistical significance was assessed by Student's t test. At this age point the hph-l mouse brain BH, concentration i s decreased by approx. 50% when compared with controls [8] . lism. Despite this, such treatment appears to be incomplete, since in a significant number of patients neurological impairment is still apparent [41] . T h e reason for this failure of treatment is unclear but, in view of the above findings, this may be related to a failure to correct cerebral NO metabolism.
Conclusions
There is growing evidence to support the involvement of NO and ONOO-in the pathogenesis of certain neurological disorders. In neurodegnerative disorders such as MS, a possible mechanism may involve damage by glial-derived ONOO-to the oligodendrocyte and neuronal mitochondrial respiratory chain. If this proves to be the case, then clinical studies involving specific NOS inhibitors will no doubt ensue. In this light, it is also conceivable that some current treatments may exert their effects by altering NO
metabolism. An example may be interferon P which is being used in the treatment of certain forms of MS [42] . Recently, we have found that preparations containing interferon P impair the ability of astrocytes to induce NOS when subsequently exposed to interferon y [43] . Since NO generation may also be beneficial at certain stages of a disease, then the use of NOS inhibitors as potential therapeutic agents will have to be carefully targeted.
In contrast with the mitochondrial respiratory chain, our understanding of the metabolic consequences of alterations in G3PDH activity are not known. The apparent tight regulation of this enzyme by NO suggests that it may have important roles in the development of neurological disorders associated with either increased or decreased NO generation.
